By Ian Ingram
Study identifies subgroup for whom another go could be worthwhile.
Lack of response to a PARP inhibitor in epithelial ovarian cancer didn’t necessarily mean patients were resistant to all such agents, a small retrospective study indicated.
Among … Read more
By Ian Ingram
In delaying disease progression in recurrent ovarian cancer, maintenance therapy with the PARP inhibitor niraparib (Zejula) also increased patients’ time without symptoms or toxicity (TWiST), an analysis of the phase III NOVA trial found.
Compared with placebo, … Read more
Since tumors often have unique defects in the DNA damage response (DDR) pathway, identifying the molecular mechanisms that underlie how cells repair various DNA lesions is critical to selecting the appropriate clinical treatments. Inhibitors to poly-(ADP-ribose) polymerase (PARP) are examples … Read more
By Will Pass
Women who have survived epithelial ovarian cancer (EOC) more often report severe long-term fatigue than healthy women, according to a case-control study involving more than 600 individuals.
Ovarian cancer survivors had a higher rate of sleep disturbance, … Read more
Ovarian cancer is not the most common form of cancer, but it’s among the deadliest. That’s because about 70 percent of cases recur. A new study by researchers at the University of Pittsburgh, UPMC Hillman Cancer Center, Magee-Women’s Research Institute … Read more
By Susan Moench
The results from the Lymphadenectomy in Ovarian Neoplasms (LION) trial, published in the New England Journal of Medicine, which compared systematic pelvic and paraaortic lymphadenectomy with no lymphadenectomy in some women with advanced ovarian cancer, showed … Read more
By Maria Cohut
Some types of cancer, such as ovarian cancer, tend to remain undetected until they are too advanced for treatment to be effective. Now, an innovative tool may be able to detect cancer easily, quickly, and in minuscule … Read more
By Dave Levitan
Conservative management of adnexal masses classified as benign was associated with a low risk of subsequent malignant ovarian cancer, according to a new study.
“Adnexal masses are often detected incidentally and most of them prove to be … Read more
A brand new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has shown promise in patients with six different cancer types.
In patients with advanced, drug-resistant cancers, over a quarter with cervical and … Read more
A recent study conducted at Denmark’s Vejle Hospital, published in Pharmacological Research, provides evidence of delta-tocotrienol’s benefits for cancer patients. Results of the open-label trial suggest that American River Nutrition-manufactured delta-tocotrienol in combination with bevacizumab had additive effects in chemotherapy … Read more
Women may not need to undergo surgery for non-cancerous ovarian cysts, avoiding potential surgical complications.
This is the finding of new research, by a team of international scientists from institutions including Imperial College London and KU Leuven, published in The … Read more
Two new papers, published simultaneously in Nature Communications and led by researchers at McGill University, offer promise that a drug currently used to treat estrogen positive breast cancer may be effective in treating two different types of cancer, one rare … Read more
By Kristi Rosa
Data from a retrospective study suggests an adjuvant gastrointestinal (GI)-based chemotherapy regimen is more beneficial than one that is gynecologic-based in patients with mucinous ovarian cancer, said Katherine C. Kurnit, MD.
“Right now, mucinous ovarian cancer is … Read more
Immune cells called macrophages are supposed to serve and protect, but cancer has found ways to put them to sleep. Now researchers at the Abramson Cancer Center of the University of Pennsylvania say they’ve identified how to fuel macrophages with … Read more
Researchers at The Institute of Cancer Research, London (ICR) have developed an artificial intelligence (AI) test that analyses the shape of tumour cells to identify patients with aggressive ovarian cancer.
The test is intended to enable tailored treatment based on … Read more
